Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony–Stimulating Factor (FIRSTLINE-AMI)
Background— Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNC CD34+ ), we tested the impact of G-CSF integrated into primary percutaneous coronary interv...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 112; no. 20; pp. 3097 - 3106 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
15.11.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background—
Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNC
CD34+
), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man.
Methods and Results—
Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89±35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 μg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, β-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNC
CD34+
were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNC
CD34+
to between 3.17±2.93 MNC
CD34+
/μL at baseline and 64.55±37.11 MNC
CD34+
/μL on day 6 (
P
<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNC
CD34+
liberation led to enhanced resting wall thickening in the infarct zone of between 0.29±0.22 and 0.99±0.32 mm versus 0.49±0.29 mm in control subjects (
P
<0.001); under inotropic challenge with dobutamine (10 μg · kg
−1
· min
−1
), wall motion score index showed improvement from 1.66±0.23 to 1.41±0.21 (
P
<0.004 versus control) and to 1.35±0.24 after 4 months (
P
<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24±0.31 mm (
P
<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41±0.25 (
P
<0.001 versus control), left ventricular end-diastolic diameter to 55±5 mm (
P
<0.002 versus control), and ejection fraction to 54±8% (
P
<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and
18
F-deoxyglucose uptake in the infarct zone (
P
<0.001 versus control).
Conclusions—
G-CSF and mobilization of MNC
CD34+
after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis. |
---|---|
AbstractList | Background—
Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNC
CD34+
), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man.
Methods and Results—
Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89±35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 μg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, β-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNC
CD34+
were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNC
CD34+
to between 3.17±2.93 MNC
CD34+
/μL at baseline and 64.55±37.11 MNC
CD34+
/μL on day 6 (
P
<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNC
CD34+
liberation led to enhanced resting wall thickening in the infarct zone of between 0.29±0.22 and 0.99±0.32 mm versus 0.49±0.29 mm in control subjects (
P
<0.001); under inotropic challenge with dobutamine (10 μg · kg
−1
· min
−1
), wall motion score index showed improvement from 1.66±0.23 to 1.41±0.21 (
P
<0.004 versus control) and to 1.35±0.24 after 4 months (
P
<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24±0.31 mm (
P
<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41±0.25 (
P
<0.001 versus control), left ventricular end-diastolic diameter to 55±5 mm (
P
<0.002 versus control), and ejection fraction to 54±8% (
P
<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and
18
F-deoxyglucose uptake in the infarct zone (
P
<0.001 versus control).
Conclusions—
G-CSF and mobilization of MNC
CD34+
after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis. Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNCCD34+), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man.BACKGROUNDConsidering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNCCD34+), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man.Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89+/-35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, beta-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNCCD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNCCD34+ to between 3.17+/-2.93 MNCCD34+/microL at baseline and 64.55+/-37.11 MNCCD34+/microL on day 6 (P<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNCCD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29+/-0.22 and 0.99+/-0.32 mm versus 0.49+/-0.29 mm in control subjects (P<0.001); under inotropic challenge with dobutamine (10 microg.kg(-1).min(-1)), wall motion score index showed improvement from 1.66+/-0.23 to 1.41+/-0.21 (P<0.004 versus control) and to 1.35+/-0.24 after 4 months (P<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24+/-0.31 mm (P<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41+/-0.25 (P<0.001 versus control), left ventricular end-diastolic diameter to 55+/-5 mm (P<0.002 versus control), and ejection fraction to 54+/-8% (P<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18F-deoxyglucose uptake in the infarct zone (P<0.001 versus control).METHODS AND RESULTSFifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89+/-35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, beta-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNCCD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNCCD34+ to between 3.17+/-2.93 MNCCD34+/microL at baseline and 64.55+/-37.11 MNCCD34+/microL on day 6 (P<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNCCD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29+/-0.22 and 0.99+/-0.32 mm versus 0.49+/-0.29 mm in control subjects (P<0.001); under inotropic challenge with dobutamine (10 microg.kg(-1).min(-1)), wall motion score index showed improvement from 1.66+/-0.23 to 1.41+/-0.21 (P<0.004 versus control) and to 1.35+/-0.24 after 4 months (P<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24+/-0.31 mm (P<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41+/-0.25 (P<0.001 versus control), left ventricular end-diastolic diameter to 55+/-5 mm (P<0.002 versus control), and ejection fraction to 54+/-8% (P<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18F-deoxyglucose uptake in the infarct zone (P<0.001 versus control).G-CSF and mobilization of MNC(CD34+) after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis.CONCLUSIONSG-CSF and mobilization of MNC(CD34+) after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis. Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of CD34+ mononuclear blood stem cells (MNCCD34+), we tested the impact of G-CSF integrated into primary percutaneous coronary intervention (PCI) management of acute myocardial infarction in man. Fifty consecutive patients with ST-segment elevation myocardial infarction were subjected to primary PCI stenting with abciximab and followed up for 6 months; 89+/-35 minutes after successful PCI, 25 patients were randomly assigned in this pilot study (PROBE design) to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care, including aspirin, clopidogrel, an ACE inhibitor, beta-blocking agents, and statins. By use of CellQuest software on peripheral blood samples incubated with CD45 and CD34, mobilized MNCCD34+ were quantified on a daily basis. With homogeneous demographics and clinical and infarct-related characteristics, G-CSF stimulation led to mobilization of MNCCD34+ to between 3.17+/-2.93 MNCCD34+/microL at baseline and 64.55+/-37.11 MNCCD34+/microL on day 6 (P<0.001 versus control); there was no indication of leukocytoclastic effects, significant pain, impaired rheology, inflammatory reactions, or accelerated restenosis at 6 months. Within 35 days, G-CSF and MNCCD34+ liberation led to enhanced resting wall thickening in the infarct zone of between 0.29+/-0.22 and 0.99+/-0.32 mm versus 0.49+/-0.29 mm in control subjects (P<0.001); under inotropic challenge with dobutamine (10 microg.kg(-1).min(-1)), wall motion score index showed improvement from 1.66+/-0.23 to 1.41+/-0.21 (P<0.004 versus control) and to 1.35+/-0.24 after 4 months (P<0.001 versus control), respectively, coupled with sustained recovery of wall thickening to 1.24+/-0.31 mm (P<0.001 versus control) at 4 months. Accordingly, resting wall motion score index improved with G-CSF to 1.41+/-0.25 (P<0.001 versus control), left ventricular end-diastolic diameter to 55+/-5 mm (P<0.002 versus control), and ejection fraction to 54+/-8% (P<0.001 versus control) after 4 months. Morphological and functional improvement with G-CSF was corroborated by enhanced metabolic activity and 18F-deoxyglucose uptake in the infarct zone (P<0.001 versus control). G-CSF and mobilization of MNC(CD34+) after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of myocardium and prevention of remodeling without evidence of aggravated restenosis. |
Author | Körber, Thomas Freund, Mathias Petzsch, Michael Ince, Hüseyin Rehders, Tim Schümichen, Carl Schmidt, Heike Nienaber, Christoph A. Kleine, Hans Dieter |
Author_xml | – sequence: 1 givenname: Hüseyin surname: Ince fullname: Ince, Hüseyin organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 2 givenname: Michael surname: Petzsch fullname: Petzsch, Michael organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 3 givenname: Hans Dieter surname: Kleine fullname: Kleine, Hans Dieter organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 4 givenname: Heike surname: Schmidt fullname: Schmidt, Heike organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 5 givenname: Tim surname: Rehders fullname: Rehders, Tim organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 6 givenname: Thomas surname: Körber fullname: Körber, Thomas organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 7 givenname: Carl surname: Schümichen fullname: Schümichen, Carl organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 8 givenname: Mathias surname: Freund fullname: Freund, Mathias organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany – sequence: 9 givenname: Christoph A. surname: Nienaber fullname: Nienaber, Christoph A. organization: From the Department of Internal Medicine, Divisions of Cardiology and Hematology (H.D.K., M.F.), and the Department of Nuclear Medicine (C.S.) at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17283722$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16275869$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks1u1DAQxyNURLeFV0DmAIJDltiJ83FCUbTbRkpbtB9cI68zqYwcu7WdlZYT78C78QA8Cd4PVMGJ02hmfvMfzcdFcKa0giB4g6Mpxin-WNWLat2Uq_rutrwupziiU5rgJI6fBRNMSRImNC7OgkkURUWYxYScBxfWfvVuGmf0RXCOU5LRPC0mwc_PBiyYLXNCKzQ3ekAN9A59AeWM4KNkBi1g0B1Ioe7RZrdnlAtr5eDeMAedT2-ZPZDi21GGqQ4tHQyoAilRIzZgjgmh0Gyr5XYvVfLRAbrZac5MJ5hEteqZ4QfOt1lbQLpHV4apUWq-cxBWWmq1-_X9x9KJwfdze5k5404b9H5eL5arpr6dheVN_eFl8Lxn0sKrk70M1vPZqroOm7uruiqbkNOIupDhnPtV9byHjBQFJBEUOE1ZweKebApKKYv61Hs4J3nGEsgKBmlSJMCh8za-DN4ddR-MfhzBunYQlvupmQI92jbN84hEhHjw9QkcNwN07YMRAzO79s8lPPD2BPhlMtn7ubmwT1xG8jg7CBVHjhttrYH-CYna_Xe0f3-HD9P2-B2-9tM_tVy4w2WcYUL-h8Jv3ynHEA |
CODEN | CIRCAZ |
CitedBy_id | crossref_primary_10_1016_j_jacc_2005_12_051 crossref_primary_10_1016_j_jacc_2010_05_039 crossref_primary_10_1517_14712598_8_11_1675 crossref_primary_10_1016_j_pcad_2007_03_004 crossref_primary_10_1016_j_ahj_2006_03_012 crossref_primary_10_4061_2010_579142 crossref_primary_10_17996_anc_19_00099 crossref_primary_10_3109_14653240903580262 crossref_primary_10_1146_annurev_physiol_012110_142230 crossref_primary_10_1007_s10741_007_9047_9 crossref_primary_10_18705_1607_419X_2007_13_3_208_211 crossref_primary_10_2217_17460751_3_2_189 crossref_primary_10_5551_jat_2279 crossref_primary_10_1002_jso_23014 crossref_primary_10_1016_j_ijcard_2009_02_020 crossref_primary_10_1136_heartjnl_2013_304955 crossref_primary_10_1021_acsnano_3c02781 crossref_primary_10_1016_j_thromres_2010_11_004 crossref_primary_10_1002_prp2_451 crossref_primary_10_1016_j_jacc_2006_06_058 crossref_primary_10_1016_j_ahj_2008_03_024 crossref_primary_10_1183_09031936_00034810 crossref_primary_10_1016_j_atherosclerosis_2007_03_046 crossref_primary_10_1093_cvr_cvn202 crossref_primary_10_1016_j_amjcard_2007_03_036 crossref_primary_10_1007_s10557_007_6072_9 crossref_primary_10_1016_j_bbrc_2011_05_081 crossref_primary_10_1111_j_1549_8719_2010_00051_x crossref_primary_10_1016_j_ijcard_2008_08_033 crossref_primary_10_1007_s12265_010_9207_5 crossref_primary_10_1007_s00586_011_2020_2 crossref_primary_10_1111_j_1365_2362_2007_01861_x crossref_primary_10_1253_circj_CJ_11_0142 crossref_primary_10_1586_14779072_6_5_703 crossref_primary_10_2217_fca_10_109 crossref_primary_10_1016_j_scr_2011_05_003 crossref_primary_10_1097_HCO_0b013e3280210657 crossref_primary_10_1111_j_1600_0643_2007_00663_x crossref_primary_10_1016_S0120_5633_11_70173_5 crossref_primary_10_1016_j_bbrc_2006_03_081 crossref_primary_10_4252_wjsc_v2_i4_61 crossref_primary_10_1016_j_ijcard_2006_11_074 crossref_primary_10_1016_S1131_3587_13_70096_7 crossref_primary_10_1586_erm_09_80 crossref_primary_10_1007_BF03345729 crossref_primary_10_1038_oby_2009_494 crossref_primary_10_1016_j_yjmcc_2008_08_003 crossref_primary_10_1007_s11897_009_0034_4 crossref_primary_10_1016_j_jacc_2006_09_018 crossref_primary_10_1016_j_jacc_2006_07_044 crossref_primary_10_1093_eurheartj_ehx248 crossref_primary_10_1038_mt_2009_40 crossref_primary_10_1111_j_1365_2362_2007_01876_x crossref_primary_10_1157_13101639 crossref_primary_10_1007_s11897_007_0013_6 crossref_primary_10_2337_db15_0433 crossref_primary_10_1016_j_ijcard_2007_05_007 crossref_primary_10_1177_1074248407303139 crossref_primary_10_1152_ajpheart_00774_2008 crossref_primary_10_1016_j_jacc_2007_11_073 crossref_primary_10_1016_j_stem_2008_10_017 crossref_primary_10_1007_s00586_012_2213_3 crossref_primary_10_1002_ccd_25566 crossref_primary_10_1016_j_ijcard_2008_11_120 crossref_primary_10_1093_eurheartj_sul060 crossref_primary_10_1016_j_ijcard_2018_01_144 crossref_primary_10_1111_j_1540_8159_2007_00630_x crossref_primary_10_1016_j_ahj_2006_11_004 crossref_primary_10_1016_S0145_4145_08_70143_6 crossref_primary_10_1016_j_ijcard_2012_10_089 crossref_primary_10_1016_j_yjmcc_2011_12_016 crossref_primary_10_1080_07853890701513746 crossref_primary_10_1093_cvr_cvs132 crossref_primary_10_1111_1755_5922_12032 crossref_primary_10_1038_ncpcardio0748 crossref_primary_10_1038_ncpcardio0745 crossref_primary_10_1002_14651858_CD008844_pub2 crossref_primary_10_1016_S0025_7753_08_75491_5 crossref_primary_10_1016_j_jacc_2006_02_021 crossref_primary_10_1016_j_yjmcc_2006_11_015 crossref_primary_10_1007_s00108_006_1707_7 crossref_primary_10_1016_j_yjmcc_2008_02_277 crossref_primary_10_1007_s11033_011_0703_8 crossref_primary_10_1097_CRD_0b013e31817bd7ab crossref_primary_10_1016_j_bbrc_2009_10_074 crossref_primary_10_1007_s00395_011_0183_y crossref_primary_10_1016_j_pcad_2007_03_001 crossref_primary_10_1007_s10741_006_9486_8 crossref_primary_10_1007_s00063_009_1054_2 crossref_primary_10_1007_s12020_013_9936_8 crossref_primary_10_1016_j_tips_2007_09_002 crossref_primary_10_1080_14017430701601651 crossref_primary_10_1002_jgm_1434 crossref_primary_10_1007_s10557_006_8285_8 crossref_primary_10_1186_1479_5876_7_106 crossref_primary_10_1038_ncpcardio0737 crossref_primary_10_1016_j_jtcvs_2014_06_029 crossref_primary_10_1253_jjcsc_16_1_83 crossref_primary_10_2459_JCM_0b013e328329ac77 crossref_primary_10_1016_j_yexcr_2019_01_001 crossref_primary_10_1038_ncpcardio0731 crossref_primary_10_1111_j_1365_2613_2009_00646_x crossref_primary_10_1517_14712598_6_5_427 crossref_primary_10_1016_j_cyto_2017_10_012 crossref_primary_10_1152_ajpheart_00186_2009 crossref_primary_10_1002_dvdy_21258 crossref_primary_10_3892_mmr_2019_10120 crossref_primary_10_1016_j_lfs_2010_01_004 crossref_primary_10_1097_MOT_0b013e32830fdfc4 crossref_primary_10_1016_j_transci_2008_04_003 crossref_primary_10_1016_j_hlc_2008_09_006 crossref_primary_10_1146_annurev_pathol_2_010506_092038 crossref_primary_10_1080_14653240701431176 crossref_primary_10_1007_s12265_008_9055_8 crossref_primary_10_1080_08977190802090614 crossref_primary_10_1093_eurjhf_hfr148 crossref_primary_10_1586_14779072_4_5_745 crossref_primary_10_1016_j_athoracsur_2011_01_021 crossref_primary_10_1016_j_poamed_2015_09_001 crossref_primary_10_3109_00365513_2012_750010 crossref_primary_10_1016_j_ijcard_2007_06_067 crossref_primary_10_1016_j_ijcard_2009_03_030 crossref_primary_10_1016_j_ahj_2007_06_038 crossref_primary_10_33678_cor_2006_057 crossref_primary_10_1016_j_yjmcc_2006_10_001 crossref_primary_10_4155_tde_12_50 crossref_primary_10_1016_j_resp_2009_10_003 crossref_primary_10_1016_j_cytogfr_2018_08_003 crossref_primary_10_5124_jkma_2006_49_11_1035 crossref_primary_10_1007_s10741_010_9188_0 crossref_primary_10_1016_j_ahj_2006_09_003 crossref_primary_10_1152_ajpheart_00060_2012 crossref_primary_10_1007_s12265_008_9020_6 crossref_primary_10_1007_s10741_010_9165_7 crossref_primary_10_1016_j_ijcard_2011_11_030 crossref_primary_10_1016_j_ijcard_2008_04_004 crossref_primary_10_1007_s11936_006_0037_3 crossref_primary_10_1182_blood_2006_07_036202 crossref_primary_10_1371_journal_pone_0202823 crossref_primary_10_1016_j_exphem_2008_01_005 crossref_primary_10_1152_ajpheart_00130_2012 crossref_primary_10_1093_eurheartj_sun049 crossref_primary_10_1016_j_yjmcc_2015_07_021 crossref_primary_10_1097_BRS_0000000000000121 crossref_primary_10_1155_2012_817364 crossref_primary_10_1016_j_ijcard_2007_07_139 crossref_primary_10_1111_j_1582_4934_2009_00759_x crossref_primary_10_1016_j_yjmcc_2011_05_015 crossref_primary_10_1016_j_ijcard_2010_04_018 crossref_primary_10_1016_j_biocel_2006_04_010 crossref_primary_10_1016_j_pharmthera_2010_09_011 crossref_primary_10_1111_j_1527_5299_2007_07111_x crossref_primary_10_2459_JCM_0b013e328343d708 crossref_primary_10_1093_eurheartj_sun047 crossref_primary_10_1093_eurheartj_sun046 crossref_primary_10_1016_j_jacc_2015_03_563 crossref_primary_10_1111_j_1748_1716_2011_02259_x crossref_primary_10_1016_j_stem_2009_02_013 crossref_primary_10_1517_14712590903460286 crossref_primary_10_1016_j_crvi_2007_05_004 crossref_primary_10_1177_0748233712440136 crossref_primary_10_1016_j_exphem_2008_01_012 crossref_primary_10_1007_s10238_021_00682_3 crossref_primary_10_1016_j_trim_2006_08_005 crossref_primary_10_1016_S1885_5857_07_60168_6 crossref_primary_10_1007_s00108_006_1610_2 crossref_primary_10_1016_j_ijcard_2008_10_029 crossref_primary_10_1253_circj_CJ_08_1129 crossref_primary_10_1182_blood_2006_06_030577 crossref_primary_10_1016_j_yasu_2011_03_001 crossref_primary_10_1182_blood_2010_05_286963 crossref_primary_10_1007_s10557_006_8799_0 crossref_primary_10_1016_j_exphem_2008_01_010 crossref_primary_10_1016_j_ijcard_2011_12_007 crossref_primary_10_1007_s00395_006_0605_4 crossref_primary_10_1016_j_ijcard_2006_11_016 crossref_primary_10_1016_j_trsl_2009_06_009 crossref_primary_10_1089_wound_2012_0390 crossref_primary_10_1016_j_exphem_2008_01_008 crossref_primary_10_1016_j_jacc_2015_03_571 crossref_primary_10_1016_j_ijcard_2009_04_047 crossref_primary_10_1096_fj_05_4763fje crossref_primary_10_1586_erd_10_78 crossref_primary_10_1253_circj_CJ_10_0109 crossref_primary_10_1093_cvr_cvq301 crossref_primary_10_1093_ageing_afp244 crossref_primary_10_1093_eurheartj_sun051 |
Cites_doi | 10.1016/S0735-1097(98)00395-7 10.1016/0735-1097(96)00152-0 10.1038/nm1199 10.1038/86498 10.1016/0735-1097(94)90667-X 10.1161/01.cir.0000147609.39780.02 10.7326/0003-4819-134-8-200104170-00011 10.1046/j.1365-2141.1997.8532481.x 10.1096/fj.03-0637fje 10.1161/01.cir.0000034046.87607.1c 10.1161/01.cir.0000129770.93985.3e 10.1161/circ.100.suppl_2.Ii-247 10.1038/35070587 10.1161/01.res.0000151843.79801.60 10.1161/circ.103.23.2776 10.1056/NEJMoa012081 10.1016/S0140-6736(04)15689-4 10.1161/01.cir.0000027585.05868.67 10.1161/circ.98.24.2695 10.1161/circ.105.4.539 10.1097/00062752-200105000-00005 10.1016/S0195-668X(02)00618-8 10.1016/S0092-8674(01)00409-3 10.1161/01.cir.0000025609.13806.31 10.1016/S0140-6736(03)14232-8 10.1016/j.yjmcc.2004.03.005 10.1038/nature02446 10.1073/pnas.181177898 10.1172/JCI119070 10.1067/mtc.2002.120716 10.1038/nature02460 10.1002/stem.140090 10.1016/S0894-7317(89)80014-8 10.1097/00003072-199601000-00005 10.1023/A:1005768523234 10.1038/nm0898-929 10.1016/S0092-8674(01)00328-2 10.1161/circ.102.19.2329 10.1056/NEJM200009283431303 10.7326/0003-4819-134-8-200104170-00012 10.1161/01.cir.0000062649.63838.c9 10.1038/nm912 10.1161/01.cir.0000051460.85800.bb 10.1111/j.1749-6632.2001.tb03591.x 10.1016/S0140-6736(03)12110-1 10.1161/01.cir.0000099501.52718.70 10.1056/NEJM200106213442503 10.1016/S0140-6736(04)15695-X 10.1007/BF01728306 10.1161/01.cir.0000084828.50310.6a 10.1161/circ.81.4.2138525 10.1016/0002-9149(66)90191-3 10.1016/j.jacc.2004.08.014 |
ContentType | Journal Article |
Copyright | 2006 INIST-CNRS |
Copyright_xml | – notice: 2006 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1161/CIRCULATIONAHA.105.541433 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 3106 |
ExternalDocumentID | 16275869 17283722 10_1161_CIRCULATIONAHA_105_541433 |
Genre | Randomized Controlled Trial Journal Article |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAEJM AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AARTV AASOK AAUEB AAWTL AAXQO AAYOK AAYXX ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABXVJ ABZAD ACCJW ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACOAL ACRKK ACWDW ACWRI ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFCHL AFDTB AFEXH AFFNX AFNMH AFUWQ AGINI AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJJEV AJNWD AJNYG AJZMW ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMNEI ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C1A C45 CITATION CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GX1 H0~ H13 HZ~ H~9 IKREB IKYAY IN~ J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 N4W N9A NEJ N~7 N~B O9- OAG OAH OBH OCB OCUKA ODMTH OGEVE OHH OHT OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RLZ S4R S4S T8P TEORI TR2 UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YSK YYM YYP YZZ ZFV ZY1 ZZMQN ~H1 1CY 41~ AAQKA AASCR AASXQ ABASU ABVCZ ABXYN ABZZY ACLDA ACXJB ADFPA AEBDS AFBFQ AFMBP AFSOK AHQVU AKCTQ AKULP ALMTX AMKUR AOHHW AOQMC BS7 EEVPB EJD ERAAH FEDTE GNXGY GQDEL HLJTE HVGLF IPNFZ IQODW MVM N~M ODA P-K R58 RIG TSPGW YQJ YXB ZGI ZXP ACIJW ACRZS AWKKM CGR CUY CVF ECM EIF NPM OJAPA OLW PKN RHF 7X8 |
ID | FETCH-LOGICAL-c505t-a18c539fcfe7299e40e9166a9a3f2b9555a0f69a318287a4e79ae6494eced6493 |
ISSN | 0009-7322 1524-4539 |
IngestDate | Fri Jul 11 09:24:33 EDT 2025 Wed Feb 19 01:43:20 EST 2025 Mon Jul 21 09:11:54 EDT 2025 Tue Jul 01 02:05:08 EDT 2025 Thu Apr 24 23:08:51 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 20 |
Keywords | Myocardial infarction remodeling Preservation Stem cell Cardiovascular disease Instrumental dilatation Glucose Myocardial disease Left ventricle Granulocyte colony stimulating factor cells Heart disease Revascularization angioplasty |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c505t-a18c539fcfe7299e40e9166a9a3f2b9555a0f69a318287a4e79ae6494eced6493 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.105.541433 |
PMID | 16275869 |
PQID | 68802022 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_68802022 pubmed_primary_16275869 pascalfrancis_primary_17283722 crossref_primary_10_1161_CIRCULATIONAHA_105_541433 crossref_citationtrail_10_1161_CIRCULATIONAHA_105_541433 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2005-11-15 |
PublicationDateYYYYMMDD | 2005-11-15 |
PublicationDate_xml | – month: 11 year: 2005 text: 2005-11-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2005 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 (e_1_3_2_54_2) 2002; 425 e_1_3_2_41_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_1_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_58_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_56_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 (e_1_3_2_4_2) 1996; 94 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 (e_1_3_2_20_2) 1996; 23 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_32_2 (e_1_3_2_52_2) 2004; 110 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_57_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_55_2 e_1_3_2_2_2 (e_1_3_2_51_2) 2004; 110 16286600 - Circulation. 2005 Nov 15;112(20):3033-5 |
References_xml | – volume: 94 start-page: II-332 year: 1996 ident: e_1_3_2_4_2 publication-title: Circulation – ident: e_1_3_2_31_2 doi: 10.1016/S0735-1097(98)00395-7 – ident: e_1_3_2_30_2 doi: 10.1016/0735-1097(96)00152-0 – ident: e_1_3_2_39_2 doi: 10.1038/nm1199 – ident: e_1_3_2_12_2 doi: 10.1038/86498 – ident: e_1_3_2_25_2 doi: 10.1016/0735-1097(94)90667-X – ident: e_1_3_2_41_2 doi: 10.1161/01.cir.0000147609.39780.02 – ident: e_1_3_2_28_2 doi: 10.7326/0003-4819-134-8-200104170-00011 – ident: e_1_3_2_19_2 doi: 10.1046/j.1365-2141.1997.8532481.x – ident: e_1_3_2_57_2 doi: 10.1096/fj.03-0637fje – ident: e_1_3_2_14_2 doi: 10.1161/01.cir.0000034046.87607.1c – ident: e_1_3_2_38_2 doi: 10.1161/01.cir.0000129770.93985.3e – ident: e_1_3_2_7_2 doi: 10.1161/circ.100.suppl_2.Ii-247 – ident: e_1_3_2_10_2 doi: 10.1038/35070587 – volume: 23 start-page: 1 year: 1996 ident: e_1_3_2_20_2 publication-title: Transfus Med – ident: e_1_3_2_35_2 doi: 10.1161/01.res.0000151843.79801.60 – ident: e_1_3_2_40_2 doi: 10.1161/circ.103.23.2776 – ident: e_1_3_2_3_2 doi: 10.1056/NEJMoa012081 – ident: e_1_3_2_50_2 doi: 10.1016/S0140-6736(04)15689-4 – ident: e_1_3_2_56_2 doi: 10.1161/01.cir.0000027585.05868.67 – ident: e_1_3_2_44_2 doi: 10.1161/circ.98.24.2695 – volume: 425 start-page: 603 year: 2002 ident: e_1_3_2_54_2 publication-title: Transfusion – ident: e_1_3_2_24_2 doi: 10.1161/circ.105.4.539 – ident: e_1_3_2_53_2 doi: 10.1097/00062752-200105000-00005 – ident: e_1_3_2_18_2 doi: 10.1016/S0195-668X(02)00618-8 – ident: e_1_3_2_8_2 doi: 10.1016/S0092-8674(01)00409-3 – ident: e_1_3_2_48_2 doi: 10.1161/01.cir.0000025609.13806.31 – ident: e_1_3_2_42_2 doi: 10.1016/S0140-6736(03)14232-8 – ident: e_1_3_2_55_2 doi: 10.1016/j.yjmcc.2004.03.005 – ident: e_1_3_2_37_2 doi: 10.1038/nature02446 – ident: e_1_3_2_11_2 doi: 10.1073/pnas.181177898 – ident: e_1_3_2_5_2 doi: 10.1172/JCI119070 – ident: e_1_3_2_13_2 doi: 10.1067/mtc.2002.120716 – ident: e_1_3_2_36_2 doi: 10.1038/nature02460 – ident: e_1_3_2_17_2 doi: 10.1002/stem.140090 – volume: 110 start-page: 17-III-238. year: 2004 ident: e_1_3_2_51_2 publication-title: Circulation – ident: e_1_3_2_23_2 doi: 10.1016/S0894-7317(89)80014-8 – ident: e_1_3_2_27_2 doi: 10.1097/00003072-199601000-00005 – ident: e_1_3_2_22_2 doi: 10.1023/A:1005768523234 – ident: e_1_3_2_6_2 doi: 10.1038/nm0898-929 – ident: e_1_3_2_9_2 doi: 10.1016/S0092-8674(01)00328-2 – ident: e_1_3_2_49_2 doi: 10.1161/circ.102.19.2329 – ident: e_1_3_2_47_2 doi: 10.1056/NEJM200009283431303 – ident: e_1_3_2_29_2 doi: 10.7326/0003-4819-134-8-200104170-00012 – ident: e_1_3_2_46_2 doi: 10.1161/01.cir.0000062649.63838.c9 – ident: e_1_3_2_58_2 doi: 10.1038/nm912 – ident: e_1_3_2_33_2 doi: 10.1161/01.cir.0000051460.85800.bb – ident: e_1_3_2_2_2 doi: 10.1111/j.1749-6632.2001.tb03591.x – ident: e_1_3_2_16_2 doi: 10.1016/S0140-6736(03)12110-1 – ident: e_1_3_2_34_2 doi: 10.1161/01.cir.0000099501.52718.70 – ident: e_1_3_2_32_2 doi: 10.1056/NEJM200106213442503 – ident: e_1_3_2_43_2 doi: 10.1016/S0140-6736(04)15695-X – ident: e_1_3_2_26_2 doi: 10.1007/BF01728306 – ident: e_1_3_2_45_2 doi: 10.1161/01.cir.0000084828.50310.6a – ident: e_1_3_2_1_2 doi: 10.1161/circ.81.4.2138525 – ident: e_1_3_2_21_2 doi: 10.1016/0002-9149(66)90191-3 – ident: e_1_3_2_15_2 doi: 10.1016/j.jacc.2004.08.014 – volume: 110 start-page: 17-III year: 2004 ident: e_1_3_2_52_2 publication-title: Circulation – reference: 16286600 - Circulation. 2005 Nov 15;112(20):3033-5 |
SSID | ssj0006375 |
Score | 2.31652 |
Snippet | Background—
Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony–stimulating factor (G-CSF) mediates... Considering experimental evidence that stem cells enhance myocardial regeneration and granulocyte colony-stimulating factor (G-CSF) mediates mobilization of... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 3097 |
SubjectTerms | Adult Biological and medical sciences Blood and lymphatic vessels Blood vessels and receptors Cardiology. Vascular system Coronary Angiography Coronary heart disease Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Fluorodeoxyglucose F18 Fundamental and applied biological sciences. Psychology Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use Heart Hematopoietic Stem Cell Mobilization Humans Male Medical sciences Middle Aged Myocardial Infarction - diagnostic imaging Myocardial Infarction - physiopathology Myocardial Infarction - prevention & control Myocardial Infarction - therapy Patient Selection Positron-Emission Tomography Radiopharmaceuticals Recurrence Stem Cell Transplantation Ventricular Remodeling - physiology Vertebrates: cardiovascular system |
Title | Preservation From Left Ventricular Remodeling by Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Use of Granulocyte-Colony–Stimulating Factor (FIRSTLINE-AMI) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16275869 https://www.proquest.com/docview/68802022 |
Volume | 112 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lb9NAEIBXbZEqJISghRIeZZEQAkUOfj-OIWpJUNNDm0i5RWt7LCwSJ0qcQ_o7-UHM7Nqx0zaocHES2-tVtJ93dmbnwdjHWLcBwHc1I7Z0zfZ0TxO-B5oRhpBEPtVcJUWxf-l2h_aPkTPa22c1r6VVHraim3vjSv5nVPEcjitFyf7DyG4eiifwO44vHnGE8figMSb_idKoqgJFJpDkTXJhlHY9sWguQNa6IYMALjQTSlegbVJEyMiVwhW1iMeUmwmU3LlJJv2m9D4RpUMk4FwmDRAiIveC6RoF4UJGnuC_wTdG3ofdrNQGAfaRrVBYrnPQKDl2ttZwQpnKgmHkvylL_dAS97x3dT246F2eae1-r7RNlOkT0kVUlBi7r3JQzZKBU520znZp8_9bZwnrNKtm_vxmqape1QMFSNJMIFVW3S5KbRQBdYfl6-jnNI1zJZ_TX7BlI3EoWFBFibagmNdNW7MdlTdpM_EbZo1wU6_N45auvIbvChiXBEynd9UZXqh0xd021UpuUTl1ldKjBt58KskzKBW0r0rS3MruXV7aZ49MVHSoBsf3UeWk5Fqec8g-FD1_3dkv5b4tnrS1wHoyR4jEJFFFWnZrUXI1NXjGnhZqEG8rpp-zPciO2HE7E_lsuuafuHRMljs-R-ywX_h_HLPfdeI5Ec-JeF4jnlfE83DNbxPP7xDPkXhOxHMinlfE8zTjJfFcEs8r4nlFPHWDxPNZwv9OPFfE889bvH95wYbnZ4NOVyvqkmgR6gu5Jgw_QpSSKAFUTQOwdUAlyxWBsBIzDBzHEXri4i-DqkkIG7xAgGsHNkQQ46f1kh1kswxeMQ6JDq4FTuxath36jvBdMHC5GPpxYGHbBvPLwRxHRdJ-qh0zGUvl3TXG20jgaWeskGgwc9N0rjLXPKTR6RYxVUuP0mSZZoO9LxEaoyCigREZzFbLsYsrAVOnO04UWVXbgszXO6-8YY-r1_YtO8gXK3iHi_08PJXvwx8mEQRd |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preservation+from+left+ventricular+remodeling+by+front-integrated+revascularization+and+stem+cell+liberation+in+evolving+acute+myocardial+infarction+by+use+of+granulocyte-colony-stimulating+factor+%28FIRSTLINE-AMI%29&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Ince%2C+H%C3%BCseyin&rft.au=Petzsch%2C+Michael&rft.au=Kleine%2C+Hans+Dieter&rft.au=Schmidt%2C+Heike&rft.date=2005-11-15&rft.eissn=1524-4539&rft.volume=112&rft.issue=20&rft.spage=3097&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.105.541433&rft_id=info%3Apmid%2F16275869&rft.externalDocID=16275869 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |